Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19

WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More

Thursday April 29, 2021 0 comments Tags: Westminster, Reven Holdings, COVID-19, Fatih Uckun, Peter Lange, Michael Volk, Brian Denomme

Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix

Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix

GOLDEN -- Reven Holdings, Inc. today announced publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In the... Read More

Thursday November 12, 2020 0 comments Tags: Golden, Reven Holdings, Reven Pharmaceuticals, COVID-19, Rejuveinix, Fatih Uckun, Peter Lange, Brian Denomme